Bnb Plus Corp. (NASDAQ: BNBX)

Applied DNA Sciences Inc., often recognized by its stock symbol APDN, operates within the biotechnology industry, specializing in the development and commercialization of technologies for DNA and RNA production and detection. The company is segmented into three primary business markets: Therapeutic DNA Production Services, Molecular Diagnostics and Genetic Testing Services, and DNA Tagging and Security Products and Services.

The Therapeutic DNA Production Services segment of APDN focuses on the development and commercialization of its Linea DNA platform. This innovative technology facilitates the rapid, efficient, and large-scale manufacture of high-fidelity DNA sequences for utilization in the production of nucleic acid-based therapeutics. The Linea DNA platform offers several advantages over existing cell-based plasmid DNA manufacturing platforms, including enhanced speed, scalability, purity, simplicity, and flexibility. APDN plans to introduce various quality grades of Linea DNA, such as GLP, GMP, and GMP for Starting Materials DNA, which will each have distinct permitted uses.

APDN's Molecular Diagnostics and Genetic Testing Services segment operates through its clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL). ADCL is a New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP)-permitted and Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, currently permitted for virology and pending genetics permitting. APDN's PGx Testing Services utilize a 120-target PGx panel test to evaluate the unique genotype of a specific patient, helping to guide individual drug therapy decisions.

APDN's DNA Tagging and Security Products and Services segment provides DNA tagging and authentication services for various industries, including textiles, nutraceuticals, and pharmaceuticals. These services, marketed under the trademark CertainT, include SigNature Molecular Tags, SigNify portable DNA readers, and fiberTyping and other product genotyping services.

APDN's competitive advantages include its proprietary Linea DNA platform, expertise in DNA detection via polymerase chain reaction (PCR), and its capability to provide a diverse range of DNA-based products and services. In the nucleic acid-based therapeutic, biologics, and DNA manufacturing markets, APDN competes with companies like MilliporeSigma, Precigen, Inc., Aldevron, LLC, and others. In the veterinary therapeutic and biologics space, APDN competes with Zoetis, Inc., Merck Animal Health, and others. In the molecular and genetic diagnostic space, APDN competes with companies such as 23andMe, Inc., Laboratory Corporation of America (LabCorp), and others.

Revenues for APDN are generated from its Therapeutic DNA Production Services, Molecular Diagnostics and Genetic Testing Services, and DNA Tagging and Security Products and Services segments. The company's largest customers include two customers in its MDx Testing Services segment, which accounted for 65% and 14% of its revenues for the fiscal year ended September 30, 2023. The DNA Tagging and Security Products and Services segment contributed 15% of the revenues for the same period.

APDN's product and service offerings include the Linea DNA platform, PGx Testing Services, SigNature Molecular Tags, SigNify portable DNA readers, and fiberTyping and other product genotyping services. These offerings cater to a wide range of industries, including pharmaceutical and biotechnology, research institutions, and government agencies.